Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study

Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
Bristol Myers Squibb, Princeton, NJ
Bristol Myers Squibb, Princeton, NJ
Intermountain Healthcare, Loveland Clinic for Blood Cancer Therapy, Salt Lake City, UT
Levine Cancer Institute, Atrium Health, Charlotte, NC
BMT and Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI
Markey Cancer Center, University of Kentucky, Lexington, KY
Bristol Myers Squibb, Seattle, WA
Evidera, Bethesda, MD
Evidera, Bethesda, MD
University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA
Vol. 109 No. 3 (2024): March, 2024